2010, Number 09-10
<< Back Next >>
Medicina & Laboratorio 2010; 16 (09-10)
Utilidad clínica de los marcadores tumorales
Campuzano MG
Language: Spanish
References: 379
Page: 411-445
PDF size: 743.12 Kb.
ABSTRACT
Tumor markers, also called biological markers or biomarkers, are defined as molecules, substances or processes that are qualitatively or quantitatively altered as a result of a precancerous condition or cancer, detectable by laboratory testing in blood, body fluids or in tissues. The nature of the tumor markers is highly variable, ranging from nucleic acid, DNA or RNA, a protein or peptide, to complex processes such as an antibody, apoptosis, proliferation or amylogenesis. From the point of view of their origin, tumor markers are produced by the tumor itself, such as the chorionic gonadotropin in choriocarcinoma, or in response to the tumor by the surrounding tissue, such as the carcinoembryonic antigen in breast cancer. There is no ideal tumor marker, defined as those with a sensitivity and specificity of 100%. Tumor markers may be used for screening people with risk of developing cancer, for early detection of confined and potentially curable disease, as part of the diagnosis, the differential diagnosis, as a prognostic and predictive value test, as a tool to assess the treatment administered, and for the detection of relapse if the patient has a new opportunity for treatment before clinical manifestations reappear. This module analyzes the main tumor markers available in our media, such as the carcinoembryonic antigen, alpha-fetoprotein, prostate specific antigen, CA 15-3, CA 125, CA 19-9, Cyfra 21-1, chorionic gonadotropin, calcitonin, ferritin and beta 2 microglobulin, among other markers. Furthermore, other subrogated markers, such as
Helicobacter pylori and papillomavirus infection will be discussed.
REFERENCES
Freedman DB, Hooper J, Wood PJ, Worthington DJ, Price CP. Challenges at the Clinical Interface: Case Histories for Clinical Biochemists. USA: AACC Press, 2001, p. 1-252.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
Piñeros M, Ferlay J, Murillo R. Cancer incidence estimates at the national and district levels in Colombia. Salud Publica Mex 2006;48:455-465.
Chan DW, Schwartz MK. Tumor markers: Introduction and general principles. In: Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications edited by Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK. Washington, D. C.: AACC Press, 2002, p. 9-17.
República de Colombia, Comisión de Regulación en Salud. Acuerdo 3 de 2009 (julio 30) por el cual se aclaran y se actualizan integralmente los Planes Obligatorios de Salud de los Regímenes Contributivo y Subsidiado.
República de Colombia. Ley 100 de 1993 (diciembre 23) por la cual se crea el sistema de seguridad social integral y se dictan otras disposiciones.
Duffy MJ. Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med 2007;18:175-184.
Bence-Jones H. On a new substance occurring in the urine of a patient with “mollities ossium”. Philos Trans 1848;138:55-62.
Beetham R. Detection of Bence-Jones protein in practice. Ann Clin Biochem 2000;37 ( Pt 5):563-570.
Graziani M, Merlini G, Petrini C. Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 2003;41:338-346.
Brown WH. A case of pruriglandular syndrome: diabetes of bearded women Lancet 1928;ii:1022-1023.
Ascheim S, Zondek B. Das Hormon Der Hypophysenvorderlapens: Testobjeckt zum nachweis des hormons Klin Wochenschr 1927;6:248-252.
Acid Phosphatase and Prostatic Cancer. Br Med J 1943;1:571-572.
Diamandis EP. Tumor markers: Past, present, and future. In: Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications edited by Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK. Washington, D. C.: AACC Press, 2002, p. 3-8.
Gutman AB, Gutman EB. An “ Acid “ Phosphatase Occurring in the Serum of Patients with Metastasizing Carcinoma of the Prostate Gland. J Clin Invest 1938;17:473-478.
Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-163.
Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS. Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation 1963;1:174-180.
Gold P, Freedman SO. Demonstration of tumorspecific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439-462.
Berson SA, Yalow RS. Isotopic tracers in the study of diabetes. Adv Biol Med Phys 1958;6:349-430.
Köhler G, Milstein C. Continous culture of fused cells secreting antiined antibody of predefined specificity. Nature 1975;256:495-497.
Huebner RJ, Todaro GJ. Oncogenes of RNA tumor viruses as determinants of cancer. Proc Natl Acad Sci U S A 1969;64:1087-1094.
Yunis JJ. Specific fine chromosomal defects in cancer: an overview. Hum Pathol 1981;12:503-515.
Campuzano-Maya G. Marcadores tumorales. Conceptos generales y aplicación clínica. Laboratorio Al Día 1995;5:143-160.
Schrohl AS, Holten-Andersen M, Sweep F, Schmitt M, Harbeck N, Foekens J, et al. Tumor markers: from laboratory to clinical utility. Mol Cell Proteomics 2003;2:378-387.
Zeidman I. The fate of circulating tumors cells. I. Passage of cells through capillaries. Cancer Res 1961;21:38-39.
Keung YK, Beaty M, Powell BL, Molnar I, Buss D, Pettenati M. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res 2004;28:579-586.
Zaccaria A, Testoni N, Valenti AM, Luatti S, Tonelli M, Marzocchi G, et al. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. Cancer Genet Cytogenet 2010;199:76-80.
Stock W. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma 2010;51:188-198.
Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. Ann Oncol 2008;19:614-622.
Roulston JE, Leonard RCF. Serological tumor markers: an introduction. Singapore: Longman Singapore Publishers Ltd, 1993.
Jain S, Bhojwani AG, Mellon JK. Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. Postgrad Med J 2002;78:646-650.
Bombardieri E, Massaron S, Martinetti A, Seregni E. Cost-effectiveness of tumor marker detection in cancer patients. Int J Biol Markers 1997;12:47-48.
Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Ann Oncol 2010;21:448-458.
Roulston JE. Limitations of tumour markers in screening. Br J Surg 1990;77:961-962.
Dreyfuss JH. Fecal occult blood testing has great potential as a screening tool for colorectal cancer. CA Cancer J Clin 2010;60:275-276.
Duffy MJ, van Rossum LGM, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer 2011;3-11.
Lim YK, Kam MH, Eu KW. Carcinoembryonic antigen screening: how far should we go? Singapore Med J 2009;50:862-865.
Mandel JS. Screening of patients at average risk for colon cancer. Med Clin North Am 2005;89:43-59, vii.
Agrawal J, Syngal S. Colon cancer screening strategies. Curr Opin Gastroenterol 2005;21:59-63.
Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010;19:1766-1774.
Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010;60:99-119.
Choconta-Piraquive LA, Alvis-Guzman N, De la Hoz-Restrepo F. How protective is cervical cancer screening against cervical cancer mortality in developing countries? The Colombian case. BMC Health Serv Res 2010;10:270.
Shi JF, Belinson JL, Zhao FH, Pretorius RG, Li J, Ma JF, et al. Human papillomavirus testing for cervical cancer screening: results from a 6-year prospective study in rural China. Am J Epidemiol 2009;170:708-716.
Ogilvie GS, van Niekerk DJ, Krajden M, Martin RE, Ehlen TG, Ceballos K, et al. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer 2010;10:111.
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100:492-501.
Wong AK, Chan RC, Nichols WS, Bose S. Human papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay. J Clin Microbiol 2008;46:869-875.
Harrison JD, Stanley J, Morris DL. CEA and CA 19.9 in gastric juice and serum: an aid in the diagnosis of gastric carcinoma? Eur J Surg Oncol 1989;15:253-257.
Chung HW, Kim JW, Lee JH, Song SY, Chung JB, Kwon OH, et al. Comparison of the validity of three biomarkers for gastric cancer screening: carcinoembryonic antigen, pepsinogens, and high sensitive C-reactive protein. J Clin Gastroenterol 2009;43:19-26.
Wiwanitkit V. Helicobacter pylori screening to prevent gastric cancer: an economical analysis for a tropical developing country. Asian Pac J Cancer Prev 2010;11:571-572.
Nomura A, Stemmermann GN. Helicobacter pylori and gastric cancer. J Gastroenterol Hepatol 1993;8:294-303.
Nobuta A, Asaka M, Sugiyama T, Kato M, Hige S, Takeda H, et al. Helicobacter pylori infection in two areas in Japan with different risks for gastric cancer. Aliment Pharmacol Ther 2004;20 Suppl 1:1-6.
Ferreccio C, Rollan A, Harris PR, Serrano C, Gederlini A, Margozzini P, et al. Gastric cancer is related to early Helicobacter pylori infection in a high-prevalence country. Cancer Epidemiol Biomarkers Prev 2007;16:662-667.
Kato M, Asaka M. Recent knowledge of the relationship between Helicobacter pylori and gastric cancer and recent progress of gastroendoscopic diagnosis and treatment for gastric cancer. Jpn J Clin Oncol 2010;40:828-837.
Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194.
Xie F, O’Reilly D, Ferrusi IL, Blackhouse G, Bowen JM, Tarride JE, et al. Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada. J Am Coll Radiol 2009;6:317-323.
Campuzano-Maya G. Prueba de aliento con 13C-urea en el diagnóstico de Helicobacter pylori. Anales de la Academia de Medicina de Medellín 1999;12:25-37.
Campuzano-Maya G. Diagnóstico no-invasivo de Helicobacter pylori: ¿serología, prueba de aliento con 13C-urea o antígenos de Helicobacter pylori en materia fecal? . Medicina & Laboratorio 2007;13:211-232.
Campuzano-Maya G. An optimized 13C-urea breath test for the diagnosis of H pylori infection. World J Gastroenterol 2007;13:5454-5464.
Snyder CF, Frick KD, Kantsiper ME, Peairs KS, Herbert RJ, Blackford AL, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol 2009;27:1054-1061.
Schmutzler RK, Engel C, Schreer I. Screening in Women at Elevated Risk for Breast Cancer. J Clin Oncol 2010.
Renshaw C, Jack RH, Dixon S, Moller H, Davies EA. Estimating attendance for breast cancer screening in ethnic groups in London. BMC Public Health 2010;10:157.
Petitti DB, Calonge N, LeFevre ML, Melnyk BM, Wilt TJ, Schwartz JS. Breast cancer screening: from science to recommendation. Radiology 2010;256:8-14.
Weigel S, Batzler WU, Decker T, Hense HW, Heindel W. First epidemiological analysis of breast cancer incidence and tumor characteristics after implementation of populationbased digital mammography screening. Rofo 2009;181:1144-1150.
Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997;60:1013-1020.
Jara L, Ampuero S, Santibanez E, Seccia L, Rodriguez J, Bustamante M, et al. BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet 2006;166:36-45.
Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007;7:937-948.
Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, et al. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 2007;103:225-232.
Torres d, Umaña A, Robledo JF, Caicedo JJ, Quintero E, Orozco A, et al. Estudio de factores genéticos para cáncer de mama en Colombia. Univ Med Bogotá 2009;50:297-301.
Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyerajah A, Weidemann P, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996;313:1355-1358.
Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynaecol 1998;105:1136-1147.
Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-1210.
Hakama M, Stenman UH, Knekt P, Jarvisalo J, Hakulinen T, Maatela J, et al. CA 125 as a screening test for ovarian cancer. J Med Screen 1996;3:40-42.
Rosenthal AN, Jacobs IJ. The role of CA 125 in screening for ovarian cancer. Int J Biol Markers 1998;13:216-220.
Roupa Z, Faros E, Raftopoulos V, Tzavelas G, Kotrotsiou E, Sotiropoulou P, et al. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening. In Vivo 2004;18:831-836.
Jacobs IJ, Oram DH, Bast RC, Jr. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol 1992;80:396-399.
De Koning HJ, Schroder FH. PSA screening for prostate cancer: the current controversy. Ann Oncol 1998;9:1293-1296.
Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004;101:894-904.
Hara N, Kitamura Y, Saito T, Komatsubara S. Total and free prostate-specific antigen indexes in prostate cancer screening: value and limitation for Japanese populations. Asian J Androl 2006;8:429-434.
McDowell ME, Occhipinti S, Gardiner RA, Baade PD, Steginga SK. A review of prostatespecific antigen screening prevalence and risk perceptions for first-degree relatives of men with prostate cancer. Eur J Cancer Care (Engl) 2009;18:545-555.
Pienta KJ. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. Urology 2009;73:S11-20.
Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009;101:1325-1329.
Horwich A, Parker C, Bangma C, Kataja V. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v129-133.
Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, et al. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst 2010;102:352-355.
van Leeuwen PJ, van Vugt HA, Bangma CH. The implementation of screening for prostate cancer. Prostate Cancer Prostatic Dis 2010;13:218-227.
Strope SA, Andriole GL. Prostate cancer screening: current status and future perspectives. Nat Rev Urol 2010;7:487-493.
Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60:70-98.
Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009;115:3879-3886.
Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol 2010;7:101-109.
Strom BL, Maislin G, West SL, Atkinson B, Herlyn M, Saul S, et al. Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer 1990;45:821-824.
Regan LS. Screening for hepatocellular carcinoma in high-risk individuals. A clinical review. Arch Intern Med 1989;149:1741-1744.
Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, et al. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol 2010;25:1426-1434.
Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127:S108-112.
Wiwanitkit V. Alpha fetoprotein for screening for hepatocellular cancer in populations with viral hepatitis B: an appraisal of Thai reports. Asian Pac J Cancer Prev 2005;6:535-536.
Tai WC, Hu TH, Wang JH, Hung CH, Lu SN, Changchien CS, et al. Clinical implications of alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc 2009;108:210-218.
Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2010.
Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer 2011;128:176-184.
Ko C, Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling RK, et al. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int 2007;27:1394-1401.
Woods WG, Tuchman M, Robison LL, Bernstein M, Leclerc JM, Brisson LC, et al. A population- based study of the usefulness of screening for neuroblastoma. Lancet 1996;348:1682-1687.
Campuzano-Maya G. Helicobacter pylori y los linfomas MALT del estómago. Medicina & Laboratorio 2006;12:111-142.
Suzuki H, Saito Y, Hibi T. Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: Updated review of clinical outcomes and the molecular pathogenesis. Gut Liver 2009;3:81-87.
Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol 2009;20:1086-1093.
Wundisch T, Thiede C, Morgner A, Dempfle A, Gunther A, Liu H, et al. Long-term followup of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-8024.
Luminari S, Cesaretti M, Marcheselli L, Rashid I, Madrigali S, Maiorana A, et al. Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas. Ann Oncol 2010;21:855-859.
Milano AE. Prostate cancer and life insurance. J Insur Med 2000;32:96-108.
Fedewa SA, Etzioni R, Flanders WD, Jemal A, Ward EM. Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev 2010;19:2437-2444.
Stout RL, Fulks M, Dolan VF, Magee ME, Suarez L. Increased mortality associated with elevated carcinoembryonic antigen in insurance applicants. J Insur Med 2007;39:251-258.
Ho CH, Lin WC, Pu YS, Yu HJ, Huang CY. Primary mucinous adenocarcinoma of renal pelvis with carcinoembryonic antigen production. Urology 2008;71:984 e987-988.
Zeng Z, Cohen AM, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. Dis Colon Rectum 1993;36:1063-1068.
Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997;185:55-59.
Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 1998;228:59-63.
Albanopoulos K, Armakolas A, Konstadoulakis MM, Leandros E, Tsiompanou E, Katsaragakis S, et al. Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am J Gastroenterol 2000;95:1056-1061.
Dixon MR, Haukoos JS, Udani SM, Naghi JJ, Arnell TD, Kumar RR, et al. Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Arch Surg 2003;138:962-966.
Quentmeier A, Moller P, Schwarz V, Abel U, Schlag P. Carcinoembryonic antigen, CA 19-9, and CA 125 in normal and carcinomatous human colorectal tissue. Cancer 1987;60:2261-2266.
Safi F, Bittner R, Roscher R, Kubel R, Beger HG. The value of CA 19-9 in gastric and colorectal carcinoma. Cancer Invest 1987;5:401-407.
Chester SJ, Maimonis P, Vanzuiden P, Finklestein M, Bookout J, Vezeridis MP. A new radioimmunoassay detecting early stages of colon cancer: a comparison with CEA, AFP, and Ca 19-9. Dis Markers 1991;9:265-271.
von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996;16:2325-2331.
Chen SW, Liang JA, Hung YC, Yeh LS, Chang WC, Yang SN, et al. Clinical implications of elevated pretreatment carcinoembryonic antigen in patients with advanced squamous cell carcinoma of the uterine cervix. Tumour Biol 2008;29:255-261.
Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 1997;90:441-447.
Jhang H, Chuang L, Visintainer P, Ramaswamy G. CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. Am J Obstet Gynecol 2003;188:1195-1197.
Park SH, Ku KB, Chung HY, Yu W. Prognostic significance of serum and tissue carcinoembryonic antigen in patients with gastric adenocarcinomas. Cancer Res Treat 2008;40:16-21.
Omar YT, al-Naqeeb N, el Nas SA, Awwad AH, Foudeh MO, Safadi NB, et al. Serum levels of CA 125 in patients with gastrointestinal cancers. Tumour Biol 1989;10:316-323.
Rosen AC, Klein M, Rosen HR, Graf AH, Lahousen M, Reiner A, et al. Preoperative and postoperative CA-125 serum levels in primary fallopian tube carcinoma. Arch Gynecol Obstet 1994;255:65-68.
Steward AM, Nixon D, Zamcheck N, Aisenberg A. Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress. Cancer 1974;33:1246-1252.
Pathak KA, Khanna R, Khanna HD, Khanna S, Gupta S, Khanna NN. Carcinoembryonic antigen: an invaluable marker for advanced breast cancer. J Postgrad Med 1996;42:68-71.
Sundblad AS, Pellicer EM, Ricci L. Carcinoembryonic antigen expression in stages I and II breast cancer: its relationship with clinicopathologic factors. Hum Pathol 1996;27:297-301.
Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989;64:1674-1681.
Pectasides D, Pavlidis N, Gogou L, Antoniou F, Nicolaides C, Tsikalakis D. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am J Clin Oncol 1996;19:459-464.
Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 1999;36 ( Pt 5):579-586.
Seker D, Kaya O, Adabag A, Necipoglu G, Baran I. Role of preoperative plasma CA 15-3 and carcinoembryonic antigen levels in determining histopathologic conventional prognostic factors for breast cancer. World J Surg 2003;27:519-521.
Kurebayashi J, Yamamoto Y, Tanaka K, Kohno N, Kurosumi M, Moriya T, et al. Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study. Breast Cancer 2003;10:38-44.
Nakamura T, Kimura T, Umehara Y, Suzuki K, Okamoto K, Okumura T, et al. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery. Surg Today 2005;35:19-21.
Chourin S, Georgescu D, Gray C, Guillemet C, Loeb A, Veyret C, et al. Value of CA 15-3 determination in the initial management of breast cancer patients. Ann Oncol 2009;20:962-964.
Kataja V, Castiglione M. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:10-14.
Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 2009;7:1060-1096.
Molina R, Auge JM, Farrus B, Zanon G, Pahisa J, Munoz M, et al. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem 2010;56:1148-1157.
Aebi S, Davidson T, Gruber G, Castiglione M. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2010;21 Suppl 5:v9-14.
Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2010;21 Suppl 5:v15-19.
Molina R, Jo J, Filella X, Zanon G, Farrus B, Munoz M, et al. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 1999;19:2551-2555.
Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 2002;48:1314-1320.
Molina R, Auge JM, Escudero JM, Filella X, Zanon G, Pahisa J, et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol 2010;31:171-180.
Leonard GD, Low JA, Berman AW, Swain SM. CA 125 elevation in breast cancer: a case report and review of the literature. Breast J 2004;10:146-149.
Baskic D, Ristic P, Matic S, Bankovic D, Popovic S, Arsenijevic N. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer. Biomarkers 2007;12:657-667.
Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol 2009;142:99-105.
Bast RC, Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 2010;116:2850-2853.
Hill R, Daunter B, Khoo SK, Mackay EV. Nature of carcinoembryonic antigen purified from malignant ascitic fluid of serous cystadenocarcinoma of the ovary. Mol Immunol 1981;18:647-653.
Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995;21:215-245.
Moore TL, Kupchik HZ, Marcon N, Zamcheck N. Carcinoembryonic antigen assay in cancer of the colon and pancreas and other digestive tract disorders. Am J Dig Dis 1971;16:1-7.
Shah KJ, Malleo G, Low J, Skordilis K, Makin AJ, Siriwardena AK. Duodenal duplication cyst with profound elevation of intracystic carbohydrate antigen (CA 19-9) and carcinoembryonic antigen (CEA): a rare but important differential in the diagnosis of cystic tumours of the pancreas. JOP 2006;7:200-204.
Rubin D, Warshaw AL, Southern JF, Pins M, Compton CC, Lewandrowski KB. Expression of CA 15.3 protein in the cyst contents distinguishes benign from malignant pancreatic mucinous cystic neoplasms. Surgery 1994;115:52-55.
Tempero M, Takasaki H, Uchida E, Takiyama Y, Colcher D, Metzgar RS, et al. Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma. Am J Surg Pathol 1989;13 Suppl 1:89-95.
Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110:704-709.
Paris F, Kerschen A, Jaeck D. Antigen CA 19-9 and mucinous cystadenoma of the pancreas. Br J Surg 1990;77:1250-1251.
Atkins CD. CA 19-9 and Lewis antigens in pancreatic cancer. J Clin Oncol 2009;27:2572-2573; author reply 2573.
Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993;269:57-60.
Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigenbased screening. JAMA 1993;270:948-954.
Buccheri G, Ferrigno D. Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test. Ann Thorac Surg 2003;75:973-980.
Kawachi R, Nakazato Y, Takei H, Koshi-ishi Y, Goya T. Clinical significance of preoperative carcinoembryonic antigen level for clinical stage I non-small cell lung cancer: can preoperative carcinoembryonic antigen level predict pathological stage? Interact Cardiovasc Thorac Surg 2009;9:199-202.
Wang CY, Huang MS, Huang MH, Lee HC, Hsu HS. Persistently High Serum Carcinoembryonic Antigen Levels after Surgery Indicate Poor Prognosis in Patients with Stage I Non-Small-Cell Lung Cancer. J Surg Res 2010.
Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003;24:209-218.
Sadoff L. The usefulness of carcinoembryonic antigen testing in the overall management of patients with non-small-cell lung cancer. Am J Clin Oncol 1998;21:284-286.
Hotta K, Segawa Y, Takigawa N, Kishino D, Saeki H, Nakata M, et al. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-smallcell lung cancer. Anticancer Res 2000;20:2177-2180.
Yoshimasu T, Kokawa Y, Oura S, Hirai I, Sasaki R, Tanino H, et al. Time course of carcinoembryonic antigen after resection of lung cancer: a predictor of recurrence. Cancer Sci 2003;94:741-744.
Nonaka M, Kataoka D, Yamamoto S, Bito A, Matsuoka J, Kawada T, et al. Pre-and postoperative serum carcinoembryonic antigen in primary lung adenocarcinoma. Ann Thorac Cardiovasc Surg 2004;10:281-284.
Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004;78:216-221.
Sakao Y, Tomimitsu S, Takeda Y, Natsuaki M, Itoh T. Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma. Eur J Cardiothorac Surg 2004;25:520-522.
Sawabata N, Maeda H, Yokota S, Takeda S, Koma M, Tokunaga T, et al. Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma: subnormal levels as an indicator of favorable prognosis. Cancer 2004;101:803-809.
Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M, Onitsuka T. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma. Ann Thorac Cardiovasc Surg 2004;10:76-80.
Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 2005;128:2298-2303.
Tomita M, Matsuzaki Y, Shimizu T, Hara M, Ayabe T, Onitsuka T. Prognostic determinants for lung cancer patients with preoperative high serum carcinoembryonic antigen levels. Thorac Cardiovasc Surg 2005;53:300-304.
Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Carcinoembryonic antigen level in serum and pleural lavage fluid in non-small cell lung cancer. Thorac Cardiovasc Surg 2010;58:350-353.
Kouba EJ, Lentz A, Wallen EM, Pruthi RS. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urol Oncol 2009;27:486-490.
Babjuk M, Soukup V, Pesl M, Kostirova M, Drncova E, Smolova H, et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 2008;71:718-722.
Raitanen MP. The role of BTA stat Test in followup of patients with bladder cancer: results from FinnBladder studies. World J Urol 2008;26:45-50.
Abd El Gawad IA, Moussa HS, Nasr MI, El Gemae EH, Masooud AM, Ibrahim IK, et al. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst 2005;17:193-202.
Chaube A, Tewari M, Singh U, Shukla HS. CA 125: a potential tumor marker for gallbladder cancer. J Surg Oncol 2006;93:665-669.
Shukla VK, Gurubachan, Sharma D, Dixit VK, Usha. Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder. Trop Gastroenterol 2006;27:160-165.
Meijer JA, le Cessie S, van den Hout WB, Kievit J, Schoones JW, Romijn JA, et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf) 2010;72:534-542.
Coskun A, Kiran G, Ozdemir O. CA 19-9 can be a useful tumor marker in ovarian dermoid cysts. Clin Exp Obstet Gynecol 2008;35:137-139.
Renaud MC, Plante M, Roy M. Ovarian thecoma associated with a large quantity of ascites and elevated serum CA 125 and CA 15-3. J Obstet Gynaecol Can 2002;24:963-965.
Acin P, Besses C, Centelles M, Machengs I, Sans-Sabrafen J. Elevated serum CA 125 tumor marker in chronic lymphocytic leukemia with mesothelial involvement. Am J Hematol 1996;53:281.
Bairey O, Shaklai M. Serum CA 125 levels in patients with chronic lymphocytic leukemia. Clin Lab Haematol 2005;27:57-60.
Dilek I, Ayakta H, Demir C, Meral C, Ozturk M. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol 2005;27:51-55.
Russo F, Lastoria S, Svanera G, Capobianco G, de Chiara A, Francia R, et al. Long-term followup study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin’s lymphoma. Leuk Lymphoma 2007;48:723-730.
Jacobs IJ, Rivera H, Oram DH, Bast RC, Jr. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J Obstet Gynaecol 1993;100:1120-1124.
Schutter EM, Kenemans P, Sohn C, Kristen P, Crombach G, Westermann R, et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 1994;74:1398-1406.
ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician- gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002;100:1413-1416.
Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005;15:679-691.
Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172-180.
Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997;337:242-253.
Von Eyben FE. Laboratory markers and germ cell tumors. Crit Rev Clin Lab Sci 2003;40:377-427.
Gori S, Porrozzi S, Roila F, Gatta G, De Giorgi U, Marangolo M. Germ cell tumours of the testis. Crit Rev Oncol Hematol 2005;53:141-164.
Briasoulis E, Tolis C, Bergh J, Pavlidis N. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol 2005;16 Suppl 1:i75-76.
NCCN Practice Guidelines in Oncology, v.1.2005, Occult Primary. http://www.nccn.org/professionals/physician_gls/PDF/occult.pdf Accessed 19 Sep, 2010.
Schutter EM, Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P, Verheijen RH. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol 2002;187:385-392.
Sari R, Yildirim B, Sevinc A, Bahceci F, Hilmioglu F. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology. Hepatogastroenterology 2001;48:1616-1621.
Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004;126:1757-1763.
Asher V, Hammond R, Duncan TJ. Pelvic mass associated with raised CA 125 for benign condition: a case report. World J Surg Oncol 2010;8:28.
Einhorn N, Knapp RC, Bast RC, Zurawski VR, Jr. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. Acta Oncol 1989;28:655-657.
Bassi C, Salvia R, Gumbs AA, Butturini G, Falconi M, Pederzoli P. The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3. Langenbecks Arch Surg 2002;387:281-285.
Cwik G, Wallner G, Skoczylas T, Krzyzanowski M, Ciechainski A, Madro P. Elevated tumor marker CA 19-9 in the differential diagnosis of pancreatic mass lesions. Ann Univ Mariae Curie Sklodowska Med 2004;59:213-218.
Fernandez-del Castillo C, Alsfasser G, Targarona J, Brugge WR, Warshaw AL. Serum CA 19-9 in the management of cystic lesions of the pancreas. Pancreas 2006;32:220.
Duraker N, Hot S, Polat Y, Hobek A, Gencler N, Urhan N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 2007;95:142-147.
Bedi MM, Gandhi MD, Jacob G, Lekha V, Venugopal A, Ramesh H. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol 2009;28:24-27.
Molina R, Agusti C, Mane JM, Filella X, Jo J, Joseph J, et al. CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 1994;9:96-101.
Yenisey C, Yenice S, Guner G, Guner S. Quantitation of MCA, CA 19.9, CA 125 and TSA levels in lung cancer. Biochem Soc Trans 1995;23:530S.
Bekci TT, Senol T, Maden E. The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules. J Int Med Res 2009;37:438-445.
Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-399; discussion 398-389.
Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
Partin AW, Brawer MK, Subong EN, Kelley CA, Cox JL, Bruzek DJ, et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1998;1:197-203.
Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999;54:220-224.
Beatty JD, Romero C, Brown PW, Lawrence W, Jr., Terz JJ. Clinical value of carcinoembryonic antigen: diagnosis, prognosis, and follow-up of patients with cancer. Arch Surg 1979;114:563-567.
Sener SF, Imperato JP, Chmiel J, Fremgen A, Sylvester J. The use of cancer registry data to study preoperative carcinoembryonic antigen level as an indicator of survival in colorectal cancer. CA Cancer J Clin 1989;39:50-57.
Huh JW, Oh BR, Kim HR, Kim YJ. Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol 2010;101:396-400.
Gobbi PG, Valentino F, Berardi E, Tronconi C, Brugnatelli S, Luinetti O, et al. New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer. Br J Cancer 2008;98:328-334.
Moreno Garcia V, Cejas P, Blanco Codesido M, Feliu Batlle J, de Castro Carpeno J, Belda- Iniesta C, et al. Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Colorectal Dis 2009;24:741-748.
Nazato DM, Matos LL, Waisberg DR, Souza JR, Martins LC, Waisberg J. Prognostic value of carcinoembryonic antigen distribution in tumor tissue of colorectal carcinoma. Arq Gastroenterol 2009;46:26-31.
Park JW, Lim SB, Kim DY, Jung KH, Hong YS, Chang HJ, et al. Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. Int J Radiat Oncol Biol Phys 2009;74:810-817.
Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2010;47:624-630.
Herszenyi L, Farinati F, Cardin R, Istvan G, Molnar LD, Hritz I, et al. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 2008;8:194.
Yachida S, Fukushima N, Nakanishi Y, Akasu T, Kitamura H, Sakamoto M, et al. Alpha-fetoprotein-producing carcinoma of the colon: report of a case and review of the literature. Dis Colon Rectum 2003;46:826-831.
Fujimoto S, Ohyama Y, Shrestha RD, Ohta M, Kokubun M, Koike S, et al. The presence of an aberrant type of human chorionic gonadotropin in patients with gastric or colorectal cancer. Jpn J Surg 1987;17:382-387.
Lorenzi M, Lorenzi B, Vernillo R. Serum ferritin in colorectal cancer patients and its prognostic evaluation. Int J Biol Markers 2006;21:235-241.
Speleman L, Kerrebijn JD, Look MP, Meeuwis CA, Foekens JA, Berns EM. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Head Neck 2007;29:341-350.
Duraker N, Celik AN. The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol 2001;76:266-271.
Dilege E, Mihmanli M, Demir U, Ozer K, Bostanci O, Kaya C, et al. Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer. Hepatogastroenterology 2010;57:674-677.
Liu X, Cheng Y, Sheng W, Lu H, Xu Y, Long Z, et al. Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. J Surg Oncol 2010;102:249-255.
Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-1291.
Duffy MJ. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci 2006;43:325-347.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:907-922.
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-325.
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79.
Duffy MJ, Shering S, Sherry F, McDermott E, O’Higgins N. CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers 2000;15:330-333.
McLaughlin R, McGrath J, Grimes H, Given HF. The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 2000;15:340-342.
Martin A, Corte MD, Alvarez AM, Rodriguez JC, Andicoechea A, Bongera M, et al. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer. Anticancer Res 2006;26:3965-3971.
Canizares F, Sola J, Perez M, Tovar I, De Las Heras M, Salinas J, et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol 2001;22:273-281.
Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002;86:1217-1222.
Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Altorjai G, et al. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment. BMC Cancer 2006;6:81.
Tampellini M, Berruti A, Bitossi R, Gorzegno G, Alabiso I, Bottini A, et al. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat 2006;98:241-248.
Vrdoljak DV, Knezevic F, Ramljak V. The relation between tumor marker Ca 15-3 and metastases in interpectoral lymph nodes in breast cancer patients. Saudi Med J 2006;27:460-462.
Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 2008;13:447-451.
Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, et al. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. Anticancer Res 1997;17:2903-2906.
Fehm T, Jager W, Kramer S, Sohn C, Solomayer E, Wallwiener D, et al. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 2004;24:1987-1992.
Kuida CA, Braunstein GD, Shintaku P, Said JW. Human chorionic gonadotropin expression in lung, breast, and renal carcinomas. Arch Pathol Lab Med 1988;112:282-285.
Yu H, Levesque MA, Clark GM, Diamandis EP. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 1998;4:1489-1497.
Black MH, Giai M, Ponzone R, Sismondi P, Yu H, Diamandis EP. Serum total and free prostate- specific antigen for breast cancer diagnosis in women. Clin Cancer Res 2000;6:467-473.
Yu H, Diamandis EP, Sutherland DJ. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75-79.
Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002;48:1194-1197.
Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-128.
Stephens RW, Brunner N, Janicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998;52:99-111.
Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992;44:207-212.
Fayers PM, Rustin G, Wood R, Nelstrop A, Leonard RC, Wilkinson P, et al. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer 1993;3:285-292.
Board RE, Bruijns CT, Pronk AE, Ryder WD, Wilkinson PM, Welch R, et al. Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. Int J Gynecol Cancer 2006;16 Suppl 1:18-24.
Riedinger JM, Bonnetain F, Basuyau JP, Eche N, Larbre H, Dalifard I, et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007;18:881-885.
Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 2009;115:1028-1035.
Kolwijck E, Span PN, Thomas CM, Bulten J, Sweep FC, Massuger LF. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer. Oncol Rep 2010;23:579-584.
Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:393-396.
Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003;89:1413-1417.
Rudnicki J, Agrawal AK, Grzebieniak Z, Zukrowski P, Zysko D, Jelen M, et al. Prognostic value of CA 19-9 level in resectable pancreatic adenocarcinoma. Folia Histochem Cytobiol 2010;48:249-261.
Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771.
Diblasio CJ, Kattan MW. Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer. Urology 2003;62 Suppl 1:9-18.
Pannek J, Partin AW. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Semin Urol Oncol 1998;16:100-105.
Sheaff MT, Martin JE, Badenoch DF, Baithun SI. beta hCG as a prognostic marker in adenocarcinoma of the prostate. J Clin Pathol 1996;49:329-332.
Grande M, Carlstrom K, Rozell BL, Stege R, Pousette A. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients. Clin Cancer Res 2000;6:1790-1795.
Huang SP, Huang LC, Ting WC, Chen LM, Chang TY, Lu TL, et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2009;18:3068-3074.
Ide H, Nakashima J, Kono H, Kikuchi E, Nagata H, Miyajima A, et al. Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy. Jpn J Clin Oncol 2010;40:177-180.
Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest 1995;108:163-169.
Pujol JL, Molinier O, Ebert W, Daures JP, Barlesi F, Buccheri G, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004;90:2097-2105.
Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 2010;30:3099-3102.
Niklinski J, Furman M, Laudanski J, Kozlowski M. Prognostic value of pretreatment CEA, SCCAg and CA 19-9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer Prev 1992;1:401-406.
Szturmowicz M, Slodkowska J, Zych J, Rudzinski P, Sakowicz A, Rowinska-Zakrzewska E. Frequency and clinical significance of betasubunit human chorionic gonadotropin expression in non-small cell lung cancer patients. Tumour Biol 1999;20:99-104.
Ikeda Y, Oomori H, Koyanagi N, Mori M, Kamakura T, Minagawa S, et al. Prognostic value of combination assays for CEA and CA 19-9 in gastric cancer. Oncology 1995;52:483-486.
Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 2001;22:318-322.
Nakajima K, Ochiai T, Suzuki T, Shimada H, Hayashi H, Yasumoto A, et al. Impact of preoperative serum carcinoembryonic antigen, CA 19-9 and alpha fetoprotein levels in gastric cancer patients. Tumour Biol 1998;19:464-469.
Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 2008;25:1075-1084.
Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90:6077-6084.
Seki K, Matsui H, Sekiya S. Advances in the clinical laboratory detection of gestational trophoblastic disease. Clin Chim Acta 2004;349:1-13.
Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002;8:193-199.
Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both? Future Oncol 2009;5:889-899.
Carr BI, Pancoska P, Branch RA. Low alphafetoprotein hepatocellular carcinoma. J Gastroenterol Hepatol 2010;25:1543-1549.
Zhang XF, Qi X, Meng B, Liu C, Yu L, Wang B, et al. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems. Eur J Surg Oncol 2010;36:718-724.
Nobuoka D, Kato Y, Gotohda N, Takahashi S, Nakagohri T, Konishi M, et al. Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep 2010;24:521-528.
Hsieh CB, Chen TW, Chu CM, Chu HC, Yu CP, Chung KP. Is inconsistency of alpha-fetoprotein level a good prognosticator for hepatocellular carcinoma recurrence? World J Gastroenterol 2010;16:3049-3055.
Lin CY, Kuo CS, Lu CL, Wu MY, Huang RF. Elevated serum vitamin B(12) levels in association with tumor markers as the prognostic factors predictive for poor survival in patients with hepatocellular carcinoma. Nutr Cancer 2010;62:190-197.
Vassilakopoulos TP, Nadali G, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Kontopidou FN, et al. beta(2)-microglobulin in Hodgkin’s lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. J BUON 2005;10:59-69.
Canovas A, Alonso JJ, Barreiro G, Aguirre C. Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin. Tumori 2010;96:117-121.
Rossi D, Fangazio M, De Paoli L, Puma A, Riccomagno P, Pinto V, et al. Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. Cancer 2010;116:2188-2200.
Berrebi A, Bassous L, Haran M, Shtalrid M, Shvidel L. The significance of elevated beta 2-microglobulin (b2-m) in chronic lymphocytic leukemia (CLL): Evidence of in vitro secretion following activation of CLL cells. Leuk Res 2010;34:e248-249.
Hann HW, Lange B, Stahlhut MW, McGlynn KA. Prognostic importance of serum transferrin and ferritin in childhood Hodgkin’s disease. Cancer 1990;66:313-316.
Lange PH, McIntire KR, Waldmann TA, Hakala TR, Fraley EE. Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer. N Engl J Med 1976;295:1237-1240.
De Bruijn HW, Sleijfer DT, Schraffordt Koops H, Suurmeijer AJ, Marrink J, Ockhuizen T. Significance of human chorionic gonadotropin, alpha-fetoprotein, and pregnancy-specific beta-1-glycoprotein in the detection of tumor relapse and partial remission in 126 patients with nonseminomatous testicular germ cell tumors. Cancer 1985;55:829-835.
Droz JP, Kramar A, Ghosn M, Piot G, Rey A, Theodore C, et al. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis. Cancer 1988;62:564-568.
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594-603.
Hayes DF, Bast RC, Desch CE, Fritsche H, Jr., Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-1466.
Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001;6:375-392.
Hayes DF, Ethier S, Lippman ME. New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 2006;100:237-238.
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1992;339:1-15.
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1992;339:71-85.
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;351:1451-1467.
Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists’ Collaborative Group overview. Ann Oncol 2006;17 Suppl 10:x59-62.
Oussoultzoglou E, Rosso E, Fuchshuber P, Stefanescu V, Diop B, Giraudo G, et al. Perioperative carcinoembryonic antigen measurements to predict curability after liver resection for colorectal metastases: a prospective study. Arch Surg 2008;143:1150-1158; discussion 1158-1159.
Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol 2008;15:3433-3439.
Lin JZ, Zeng ZF, Wu XJ, Wan DS, Chen G, Li LR, et al. Phase II study of pre-operative radiotherapy with capecitabine and oxaliplatin for rectal cancer and carcinoembryonic antigen as a predictor of pathological tumour response. J Int Med Res 2010;38:645-654.
Cidon EU, Bustamante R. Gastric Cancer: Tumor Markers as Predictive Factors for Preoperative Staging. J Gastrointest Cancer 2010.
Duffy MJ, Duggan C, Keane R, Hill AD, McDermott E, Crown J, et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004;50:559-563.
Huang Y, Zimmerman RL, Bibbo M. Diagnostic value of CA 15-3 antibody in detecting metastatic adenocarcinoma. Anal Quant Cytol Histol 2004;26:259-262.
Al-azawi D, Kelly G, Myers E, McDermott EW, Hill AD, Duffy MJ, et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 2006;6:220.
Sutterlin M, Bussen S, Trott S, Caffier H. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer. Anticancer Res 1999;19:2567-2570.
Given M, Scott M, Mc Grath JP, Given HF. The predictive of tumour markers CA 15-3, TPS and CEA in breast cancer recurrence. Breast 2000;9:277-280.
Soletormos G, Nielsen D, Schioler V, Mouridsen H, Dombernowsky P. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 2004;40:481-486.
Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, et al. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 2007;27:1963-1968.
Premkumar VG, Yuvaraj S, Vijayasarathy K, Gangadaran SG, Sachdanandam P. Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. Biol Pharm Bull 2007;30:367-370.
Park BW, Oh JW, Kim JH, Park SH, Kim KS, Lee KS. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008;19:675-681.
Kim MJ, Park BW, Lim JB, Kim HS, Kwak JY, Kim SJ, et al. Axillary lymph node metastasis: CA-15-3 and carcinoembryonic antigen concentrations in fine-needle aspirates for preoperative diagnosis in patients with breast cancer. Radiology 2010;254:691-697.
Lumachi F, Basso SM, Bonamini M, Marzano B, Milan E, Waclaw BU, et al. Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer. Anticancer Res 2010;30:2331-2334.
Yu H, Levesque MA, Clark GM, Diamandis EP. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostatespecific antigen in combination. Br J Cancer 1999;81:490-495.
Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani AR. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol 2004;93:131-136.
Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol 2006;17:1234-1238.
Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997;4:551-556.
Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000;82:1013-1016.
Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 2005;9:1286-1292.
Berger AC, Garcia M, Jr., Hoffman JP, Regine WF, Abrams RA, Safran H, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918-5922.
Ulmert D, Serio AM, O’Brien MF, Becker C, Eastham JA, Scardino PT, et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008;26:835-841.
Halvorsen OJ, Rostad K, Oyan AM, Puntervoll H, Bo TH, Stordrange L, et al. Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer. Clin Cancer Res 2007;13:892-897.
Chen F, Luo X, Zhang J, Lu Y, Luo R. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Med Oncol 2010;27:950-957.
Wahren B, Edsmyr F. Carcinoembryonic antigen in serum, urine and cells of patients with bladder carcinoma. Urol Res 1978;6:221-224.
Saied GM, El-Metenawy WH, Elwan MS, Dessouki NR. Urine carcinoembryonic antigen determination in urinary bladder bilharziasis predicts carcinoma in patients with premalignant lesions: observation of 43 cases in Egypt. Tanzan Health Res Bull 2006;8:122-127.
George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 2007;25:5352-5358.
Urushibara M, Kageyama Y, Akashi T, Otsuka Y, Takizawa T, Koike M, et al. HSP60 may predict good pathological response to neoadjuvant chemoradiotherapy in bladder cancer. Jpn J Clin Oncol 2007;37:56-61.
Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005;90:2029-2034.
Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007;92:450-455.
Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010.
Stella-Holowiecka B, Czerw T, Holowiecka- Goral A, Giebel S, Wojnar J, Holowiecki J. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Transplant Proc 2007;39:2893-2897.
Martin EW, Jr., Cooperman M, King G, Rinker L, Carey LC, Minton JP. A retrospective and prospective study of serial CEA determinations in the early detection of recurrent colon cancer. Am J Surg 1979;137:167-169.
Desch CE, Benson AB, 3rd, Smith TJ, Flynn PJ, Krause C, Loprinzi CL, et al. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 1999;17:1312.
Bast RC, Jr., Ravdin P, Hayes DF, Bates S, Fritsche H, Jr., Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-1878.
Rustin GJ, Bast RC, Jr., Kelloff GJ, Barrett JC, Carter SK, Nisen PD, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004;10:3919-3926.
Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821-1825.
Small EJ, Roach M, 3rd. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol 2002;29:264-273.
Tsai MC, Wang JH, Hung CH, Kee KM, Yen YH, Lee CM, et al. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2010;25:605-612.
Pauniaho SL, Tatti O, Lahdenne P, Lindahl H, Pakarinen M, Rintala R, et al. Tumor markers AFP, CA 125, and CA 19-9 in the long-term follow-up of sacrococcygeal teratomas in infancy and childhood. Tumour Biol 2010;31:261-265.
Safi F, Kohler I, Rottinger E, Beger H. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991;68:574-582.
Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 2002;38:1189-1193.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312.
Cardoso F, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol 2009;20 Suppl 4:15-18.
Pectasides D, Mylonakis A, Kostopoulou M, Papadopoulou M, Triantafillis D, Varthalitis J, et al. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 1997;20:348-353.
Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48.
Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2010;181:16-19.
Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988;6:462-468.
Micke O, Bruns F, Schafer U, Kurowski R, Horst E, Willich N. CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 2003;23:835-840.
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270:943-947.
Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol 2009;16:3087-3093.
Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N, et al. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 1999;29:550-555.
Wu SC, Chou FF, Rau KM. Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat 2010.
Tuxen MK, Soletormos G, Dombernowsky P. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer 2001;84:1301-1307.
Markman M, Petersen J, Belland A, Burg K. CA-125 monitoring in ovarian cancer: patient survey responses to the results of the MRC/ EORTC CA-125 Surveillance Trial. Oncology 2010;78:1-2.
McIntosh HM, Neal RD, Rose P, Watson E, Wilkinson C, Weller D, et al. Follow-up care for men with prostate cancer and the role of primary care: a systematic review of international guidelines. Br J Cancer 2009;100:1852-1860.
Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 2008;14:7813-7821.
Zidan J, Hussein O, Basher W, Zohar S. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin’s lymphoma. Oncologist 2004;9:417-421.
Allen KR, Degg TJ, Anthoney DA, Fitzroy-Smith D. Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples. Ann Clin Biochem 2007;44:300-307.
Sausville EA, Longo DL. Principles of cancer treatment: surgery, chemotherapy, and biologic therapy. In: Harrison’s principles of internal medicine, edited by Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. New York: McGraw-Hill, 2005, p. 465-482.
Mach JP, Vienny H, Jaeger P, Haldemann B, Egely R, Pettavel J. Long-term follow-up of colorectal carcinoma patients by repeated CEA radioimmunoassay. Cancer 1978;42:1439-1447.
Al-Shagahin H, Alkotyfan K, Muller HH, Sesterhenn AM, Werner JA. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma. Anticancer Res 2009;29:3421-3425.
Alkotyfan K, Wiegand S, Muller HH, Windfuhr JP, Werner JA, Sesterhenn AM. Cyfra 21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharynx. Anticancer Res 2010;30:2291-2296.
Dershaw DD, McCormick B, Osborne MP. Detection of local recurrence after conservative therapy for breast carcinoma. Cancer 1992;70:493-496.
Mariani L, Miceli R, Michilin S, Gion M. Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers 2009;14:130-136.
Younsi N, Montravers F, Philippe C, Seddiki M, Uzan S, Izrael V, et al. CA 15-3 and bone scintigraphy in the follow-up of breast cancer. Int J Biol Markers 1997;12:154-157.
Begic A, Kucukalic-Selimovic E, Obralic N, Duric O, Lacevic N, Begovic S, et al. Role of bone scintigraphy and tumor marker-Ca 15-3 in detection of bone metastases in patients with breast cancer. Bosn J Basic Med Sci 2005;5:23-26.
Marcus DM, Zinberg N. Measurement of serum ferritin by radioimmunoassay: results in normal individuals and patients with breast cancer. J Natl Cancer Inst 1975;55:791-795.
Jacobs A, Jones B, Ricketts C, Bulbrook RD, Wang DY. Serum ferritin concentration in early breast cancer. Br J Cancer 1976;34:286-290.
Prat A, Parera M, Adamo B, Peralta S, Perez- Benavente MA, Garcia A, et al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann Oncol 2009;20:294-297.
Pinson P, Joos G, Watripont P, Brusselle G, Pauwels R. Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer. Respiration 1997;64:102-107.
Saller B, Clara R, Spottl G, Siddle K, Mann K. Testicular cancer secretes intact human choriogonadotropin (hCG) and its free beta-subunit: evidence that hCG (+hCG-beta) assays are the most reliable in diagnosis and follow-up. Clin Chem 1990;36:234-239.
Franke WG, Zophel K, Wunderlich GR, Mat R, Kuhne A, Schimming C, et al. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study. Cancer Detect Prev 2000;24:524-530.
Batlle M, Ribera JM, Oriol A, Pastor C, Mate JL, Fernandez-Aviles F, et al. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin’s lymphoma: study of 200 patients. Leuk Lymphoma 2005;46:1471-1476.
Sacchi S, Curci G, Piccinini L, Manenti E, Bursi R, Torelli U. Serum ferritin concentration in malignant lymphomas. Panminerva Med 1985;27:29-31.
Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, et al. Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transplant 2008;14:1239-1244.
Schwartz MK. Lactic dehydrogenase. An old enzyme reborn as a cancer marker? Am J Clin Pathol 1991;96:441-443.
Watson NC, Heard SO. The use of lactate as a biomarker. J Intensive Care Med 2010;25:301-302.
Ohnishi K, Shimizu K, Yamada H. Serum ferritin and non-Hodgkin’s lymphoma. Nippon Ketsueki Gakkai Zasshi 1984;47:1012-1016.
Full text